Loading clinical trials...
Loading clinical trials...
A Single Arm，Multicenter， Phase II Clinical Study to Evaluate the Efficacy and Safety of GLS-010 Injection in the Treatment of Recurrent or Refractory Classical Hodgkin's Lymphoma
Conditions
Interventions
GLS-010
Locations
5
China
Guizhou Cancer Hospital
Guiyang, Guizhou, China
Hunan Cancer Hospital
Changsha, Hunan, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China
Peking University Cancer Hospital & Institute
Beijing, China
Start Date
August 24, 2018
Primary Completion Date
April 11, 2021
Completion Date
April 11, 2022
Last Updated
June 11, 2020
Lead Sponsor
Guangzhou Gloria Biosciences Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions